MedTrace Logo

MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors

NCT06555952 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-07-15

No results posted yet for this study

Summary

Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects of taking 150mg of MegaNatural BP GSE per day on blood pressure levels along with influences on heart health through assessing the function of the blood vessel lining and levels of inflammation.

Conditions

Interventions

DIETARY_SUPPLEMENT

MegaNatural-BP SR 150Mg Tablet

GSE MegaNatural BP

OTHER

Placebo Capsule

given in place of GSE MegaNatural BP

Sponsors & Collaborators

  • Clinical Nutrition Research Center, Illinois Institute of Technology

    lead INDUSTRY

Principal Investigators

  • Britt Burton-Freeman · 708-563-8276

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-08
Primary Completion
2026-07-22
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06555952 on ClinicalTrials.gov